Compare Banco Santander SA (SAN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs TransMedics Group Inc — how do they compare? Banco Santander SA trades at $13.49 (market cap $192.86B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Banco Santander SA is far larger — about 70.4× TransMedics Group Inc's market cap, and Banco Santander SA pays a 2.06% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and TransMedics Group Inc for 24 Days on average.
| SAN | TMDX | |
|---|---|---|
Market Cap | $192.86B | $2.74B |
Volume | 10,644,519 | 949,331 |
Sector | Financials | Health |
52-Week High | $15.05 | $150.42 |
52-Week Low | $9.65 | $61.99 |
Typical Hold Time | 55 Days | 24 Days |
Enterprise Value | $360.86B | $3.13B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.48, down 1.32% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss. Fundamentals are solid with a 26.25% net income margin and a P/E of 13.55, while cash flow trends have weakened significantly. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence.
The outlook is cautiously optimistic given strong profitability and analyst support, but risks include declining cash flows, high debt levels, and economic sensitivity. The stock's current valuation may appeal to value-oriented investors, though near-term volatility is likely.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
